Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Triple-negative breast cancer (TNBC) accounts for about 20% of clinical breast cancer. Clinical characteristics include early onset, high malignancy and heterogeneity. There is no effective drug target for TNBC, resulting in poor outcomes, high relapse rate and distant metastasis. So, further research on TNBC pathological features is particularly important. Compared with the solvent-based paclitaxel, albumin-bound paclitaxel (nab-P) demonstrates a stronger therapeutic effect. With albumin nanoparticles as a carrier, nab-P increases the concentration of extra-tumor drugs by passing through the albumin receptor (Gp60) transmembrane pathway and the secreted protein acidic and rich in cysteine (SPARC) approach that binds to the extracellular matrix of the tumor. Numerous clinical trials have found that nab-P is superior to the solvent-based paclitaxel in the treatment of breast cancer, especially in breast cancer with poor prognosis. However, the current efficacy of nab-P in the treatment of TNBC has not been fully verified. The mechanism underlying the killing effect of nab-P on TNBC breast cancer cells remains unclear yet. This trial will compare the therapeutic effect of nab-P with solvent-based paclitaxel in TNBC patients, and seek for important scientific clues, scientific evidence, and clinical data for nab-P in the treatment of TNBC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak piersi (badanie mammografii) bez receptorów estrogenowych, progesteronowych i HER2
- •Przerzuty do węzłów chłonnych w pachwie
- •Wiek 18-70 lat, kobieta
- •Dobra współpraca z pacjentem, dobrowolny udział, gotowość do losowego przydzielenia do grupy paclitaxelu lub nab-P, podpisana świadoma zgoda
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Przerzuty na odległość
- •Historia innych nowotworów lub wcześniejsza radioterapia klatki piersiowej
- •Nieprawidłowości w badaniach krwi lub objawy zakażenia
- •Alergia na paclitaxel
- •Historia uzależnienia od leków psychotropowych lub zaburzeń psychicznych
- •Nieprawidłowości w pracy serca, płuc, wątroby lub nerek
- •Uczestnictwo w innych badaniach klinicznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- July 20, 2021
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Shengjing Hospital of China Medical University
Shenyang, China
Trial contact
Xi Gu, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.